Galderma Group AG announced the successful placement of a single-tranche €500 million Eurobond as part of its ongoing refinancing strategy. The bond carries a five-year maturity and a fixed annual coupon of 3.375%.
The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026. The bond will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction.
According to the company, the net proceeds from the issuance will be used to fully repay an existing bank term loan that was issued in connection with Galderma’s initial public offering in March 2024. The refinancing represents the final step in the company’s post-IPO refinancing process.
Galderma currently holds investment-grade credit ratings of BBB with a stable outlook from Fitch and BBB with a positive outlook from S&P Global Ratings. The newly issued bond is expected to carry a BBB rating from both agencies.
The company said the transaction is leverage-neutral and is not expected to materially affect its full-year 2026 guidance for net financial expenses.
Founded in 1981, Galderma is a dermatology-focused company operating in approximately 90 countries. The company develops science-based products across injectable aesthetics, dermatological skincare and therapeutic dermatology, serving both patients and consumers through partnerships with healthcare professionals.
